Aeterna Zentaris 2017 Investor Presentation

Aeterna Zentaris presents its 2017 investment opportunity focused on two FDA submissions: Macrilen for Adult Growth Hormone Deficiency and Zoptrex for endometrial cancer. The presentation highlights commercial-stage products including Apifiny and Saizen, along with a growing portfolio strategy leveraging targeted cytotoxic therapy technology.